Skip to main content
Clinical Trials/NCT01440218
NCT01440218
Enrolling by Invitation
N/A

Idiopathic Diseases of Man (IDIOM)

Scripps Translational Science Institute1 site in 1 country10 target enrollmentSeptember 2011

Overview

Phase
N/A
Intervention
Not specified
Conditions
Rare Disease
Sponsor
Scripps Translational Science Institute
Enrollment
10
Locations
1
Primary Endpoint
Genomic sequencing of tissue
Status
Enrolling by Invitation
Last Updated
last year

Overview

Brief Summary

This research is being done to learn more about possible genetic causes of currently undiagnosed conditions, and to find out how the development of new technologies, such as DNA sequencing, can increase knowledge of the role genetic variants play in disorders and possibly how genetic variants may help de-termine the best treatment options.

The recent development of new technologies has increased our ability to understand how genetic mutations are associated with disease. Using these technologies to find the genetic variants responsible for rare diseases is a rapidly growing field and has already begun to transform the way conditions with unknown causes are diagnosed and treated.

Hypothesis: Identification of new genomic variants associated with idiopathic diseases and/or diseases of unknown etiology will advance medical knowledge about rare and common diseases.

Registry
clinicaltrials.gov
Start Date
September 2011
End Date
December 2030
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Scripps Translational Science Institute
Responsible Party
Principal Investigator
Principal Investigator

Eric Topol, MD

Director

Scripps Translational Science Institute

Eligibility Criteria

Inclusion Criteria

  • Individual with rare disorder with previous unknown etiology.
  • Individual with known disorder that does not respond to conventional treatment.
  • Individual experienced a rare adverse event that was a result of the administration of a pharmacologic or biologic agent, immunization or device.
  • Individual is a family member of the affected individual. -

Exclusion Criteria

  • Unwilling or unable to grant informed consent if they do not have a legal guardian who has authority to sign a consent form on their behalf.
  • Have a significant medical, affective, or psychiatric condition that in the Investigator's opinion may interfere with subject's study participation.

Outcomes

Primary Outcomes

Genomic sequencing of tissue

Time Frame: Day 1

Generation of genomic information that may inform the diagnosis and/or treatment of idiopathic diseases and/or diseases of unknown etiology.

Secondary Outcomes

  • Identification of modifying genomic alterations(Day 1)

Study Sites (1)

Loading locations...

Similar Trials